Heart HealthOlpasiran Slashes Lp(a) Levels in Phase 2 Cardiovascular Trial
Lipoprotein(a), or Lp(a), is a genetically determined cholesterol particle that significantly raises the risk of heart attack and stroke — yet no approved therapy can effectively lower it. This completed Phase 2 trial, sponsored by Amgen, tested olpasiran, a small interfering RNA (siRNA) drug delivered by subcutaneous injection, to see how much it could reduce Lp(a) levels compared to placebo. The OCEAN(a)-DOSE study enrolled patients with cardiovascular disease and measured percent change in Lp(a) from baseline across different olpasiran doses. Results from the completed trial established the dose-response relationship needed to advance olpasiran into larger Phase 3 outcomes trials. This represents a meaningful step forward in addressing one of cardiology's most persistent unmet needs.
